BCDA
BioCardia, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.90
−2.46%Oct 19, 2026, 13:15 UTC
The U.S. Food and Drug Administration accepted BioCardia’s pre-submission package for marketing clearance of its Helix catheter.
Source:Oct 7, 2026, 13:00 UTC
BioCardia announced that it will present a scientific poster on the CardiAMP HF II trial design at the Heart Failure Society of America Annual Scientific Meeting in Phoenix from October 9 to 12, 2026.
Source:Oct 1, 2026, 13:15 UTC
BioCardia completed a revised Pre-Submission to the FDA's Center for Devices and Radiological Health under the Q-Submission program for approval of its Helix Catheter for therapeutic and diagnostic agent delivery to the heart.
Source:Sep 23, 2026, 13:15 UTC
BioCardia provided an update on its FDA Helix pre-submission and its PMDA CardiAMP HF Shonin submission, confirming the timing of these near-term regulatory milestones.
Source:Aug 24, 2026, 12:30 UTC
BioCardia announced that the FDA confirmed the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System, supporting a follow-on De Novo pre-submission for approval.
Source:Aug 21, 2026, 00:00 UTC
BioCardia, Inc. received a notice from NASDAQ on August 19, 2026, stating that the company no longer complies with the minimum bid price requirement under Rule 5550(a)(2), and has until February 16, 2027, to regain compliance.
Aug 13, 2026, 04:47 UTC
BioCardia, Inc. held its Q2 2026 earnings call on August 12, 2026, to discuss financial results and business updates.
Source:Jun 8, 2026, 12:00 UTC
BioCardia completed a $4.4 million financing to extend its cash runway.
Source: